Zulily Inc (NASDAQ:ZU) posted the unanticipated loss for the Q1 2014 financial year that ended 30 March 30, 2014. The company reported that revenues had increased 87% y-o- to $237.9 million, primarily on the back of 93 percent growth in its active customer base that grew to 3.7M in the quarter. Zulily Inc. (NASDAQ:ZU) stock opened today at $28.75 and is currently trading at $30.30. The stock showed a negative weekly performance of -30.25%.
Home carbonated beverages maker SodaStream International Ltd. (NASDAQ:SODA) today reaffirmed its full-year guidance, after reporting flat higher revenue and sharply lower profits for the first quarter of 2014, albeit beating the analysts’ forecasts. Sodastream International Ltd (NASDAQ:SODA) stock opened at $39.56, in current trading session and currently is at $41.20, by gaining 0.19%. The 52 week range of $35.27 – $77.80. Company’s market capitalization is 860.46 million.
Hydrogenics (NASDAQ:HYGS) stock is tumbling in pre-market trading after the hydrogen energy developer announced a public offering of 1.5 million common shares (1 million from treasury and 500,000 secondary shares by CommScope, a selling shareholder).Hydrogenics Corporation (USA) (NASDAQ:HYGS) stock is currently trading at $15.26. The EPS of the stock is -1.28. Company’s market capitalization is 138.69 million.
SanDisk (SNDK) Corp. and Micron Technology, Inc. (NASDAQ:MU) Technology Inc. sell flash memory chips to smartphone makers and in the form of solid-state drives, or SSDs, for use in data centers. The number of SSDs sold for use in corporate storage will surge 39 percent a year through 2018 after reaching 4.5 million in 2013, according to researcher IHS Inc. Micron is at a 12-year peak. Micron Technology, Inc. (NASDAQ:MU) stock opened the session at $27.56, and now is at $27.56. The 52 week range of the Micron Technology, Inc. (NASDAQ:MU) stock remained $10.52 – $27.78 and the day range was $27.27 – $27.62.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, today announced that it has signed an agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet® (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet®. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) stock opened today at $6.05 and is currently trading at $5.88. The stock showed a positive weekly performance of 0.94%.
Leave a Reply